Cargando…

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3

BACKGROUND: In the double-blind, phase 3 PALOMA-2 and PALOMA-3 studies, palbociclib plus endocrine therapy (ET) demonstrated significant improvement in progression-free survival versus placebo plus ET in patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Norikazu, Mukai, Hirofumi, Inoue, Kenichi, Rai, Yoshiaki, Ohno, Shinji, Ohtani, Shoichiro, Shimizu, Chikako, Hashigaki, Satoshi, Muramatsu, Yasuaki, Umeyama, Yoshiko, Iwata, Hiroji, Toi, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925474/ https://www.ncbi.nlm.nih.gov/pubmed/33085032 http://dx.doi.org/10.1007/s12282-020-01162-4

Ejemplares similares

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
por: Mukai, Hirofumi, et al.
Publicado: (2018)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Palbociclib in combination with letrozole as first‐line treatment for advanced breast cancer: A Japanese phase II study
por: Masuda, Norikazu, et al.
Publicado: (2018)

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study
por: Im, Seock-Ah, et al.
Publicado: (2019)

Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
por: Iwata, Hiroji, et al.
Publicado: (2017)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
por: Sawaki, Masataka, et al.
Publicado: (2023)

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib
por: Zhu, Zhou, et al.
Publicado: (2022)

Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
por: Cristofanilli, Massimo, et al.
Publicado: (2022)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3
por: Rugo, Hope S., et al.
Publicado: (2022)

Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients
por: Tamura, Kenji, et al.
Publicado: (2016)

Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
por: Finn, Richard S., et al.
Publicado: (2020)

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01
por: Yamashiro, Hiroyasu, et al.
Publicado: (2020)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
por: Ueno, Takayuki, et al.
Publicado: (2019)

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2021)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
por: Harbeck, N., et al.
Publicado: (2016)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
por: Kuroi, Katsumasa, et al.
Publicado: (2014)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
por: Rugo, H S, et al.
Publicado: (2018)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

La paloma
por: Süskind, Patrick
Publicado: (1987)

Las palomas /
por: Gómez Cervantes, Teresa
Publicado: (2002)

Detente paloma
Publicado: (2006)

Las palomas
por: Garrido, Orlando H.
Publicado: (1986)

Cándidas palomas /
por: Kurtz, Carmen
Publicado: (1975)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
por: Gelmon, Karen, et al.
Publicado: (2021)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_89gjndcptoqfbcq19hqm30g8bd